FDA panel to review popular peptides amid persistent consumer appetite

FDA advisory panel meets 23-24 July to decide whether seven peptides can be compounded by licensed pharmacies, amid surging consumer demand driven by social media and biohacking communities. Panel includes members with ties to peptide businesses; staff reviewers flagged insufficient safety and efficacy data, but demand is expected to persist regardless of the outcome.

This Wire brief sits within Fusion42's coverage of Digital Health. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.